Peija Medical Announces 1st Chinese Patient Implanted with TaurusTrio™ Transcatheter Aortic Valve Replacement System

Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced on July 31, 2023 that the first Chinese patient of the multi-center registration clinical trial for TaurusTrio™ Transcatheter Aortic Valve Replacement (TAVR) system has been enrolled. TaurusTrio™ is the licensed-in Trilogy™ Heart Valve System for Aortic Regurgitation (AR) from JenaValve Technology, Inc. The first implant was successfully completed by Professors Yongjian Wu and Guangyuan Song at Beijing An Zhen Hospital, Capital Medical University on July 26, 2023.

“We are pleased to have safely implanted the first patient in China with the TaurusTrio™ TAVR System,” said Dr. Yi Zhang, Chief Executive Officer of Peija Medical. “The trial reinforces our goals of improving care in the field of cardiology and expanding TAVR systems within China. We are looking forward to our continued partnership with American company, JenaValve and presenting further data from the clinical trial at a future date.”

The clinical trial of the TaurusTrio™ TAVR system is designed to assess the safety and efficacy of the system for treating patients with native symptomatic, severe AR, who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement. The result of this clinical trial would be included in the Company’s future submission of registration application to the National Medical Products Administration (NMPA).

As of now, no transfemoral TAVR system for AR has been approved by the NMPA in China. In June 2023, TaurusTrio™ TAVR system was accepted by the Special Review and Approval Procedure for innovative medical devices of the NMPA.

In January 2022, Peijia Medical obtained an exclusive license from JenaValve for developing, manufacturing and commercializing Trilogy™ Heart Valve System in the Greater China region. On May 12, 2023, the successful completion of the first two commercial implants with the Trilogy™ Heart Valve System took place in Hong Kong.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy